Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-HAE: Donidalorsen in Hereditary Angioedema
NCT05139810Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of donidalorsen in hereditary angioedema (HAE) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Time-Normalized Investigator-Confirmed HAE Attack Rate. Started Dec 2021; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05139810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139810.